Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCJLD1)

Drug Name
SCH 727965 Drug Info
Synonyms Dinaciclib; SCH-727965
Indication
Disease Entry ICD 11 Status REF
Acute lymphoblastic leukaemia 2A85 Discontinued in Phase 3 [1]
Cross-matching ID
PubChem CID
46926350
ChEBI ID
CHEBI:95060
CAS Number
CAS 779353-01-4
TTD Drug ID
DMCJLD1

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Cyclin-dependent kinase 9 (CDK9)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Flavopiridol DMKSUOI Acute myeloid leukaemia 2A60 Phase 2 [5]
P276-00 DM9DJL2 Mantle cell lymphoma 2A85.5 Phase 2 [2]
RGB-286638 DMEGOQP Haematological malignancy 2B33.Y Phase 1 [6]
SNS-032 DMEITAS Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
BTX-A51 DMC8XHQ Advanced solid tumour 2A00-2F9Z Phase 1 [8]
CYC065 DM9ODT6 Lymphoma 2A80-2A86 Phase 1 [5]
AZD4573 DMOYPTK Haematological malignancy 2B33.Y Phase 1 [5]
TP-1287 DM3Z07E Solid tumour/cancer 2A00-2F9Z Phase 1 [9]
VIP-152 DMBQ5OL Chronic lymphocytic leukaemia 2A82.0 Phase 1 [10]
AZD7503 DM8XJD2 Non-alcoholic steatohepatitis DB92.1 Phase 1 [11]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Cyclin-dependent kinase 1 (CDK1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
R-roscovitine DMSH108 Non-small-cell lung cancer 2C25.Y Phase 2 [2]
Ro 31-7453 DM83QCL Solid tumour/cancer 2A00-2F9Z Phase 2 [12]
P276-00 DM9DJL2 Mantle cell lymphoma 2A85.5 Phase 2 [2]
P-276 DMMJUHD Breast cancer 2C60-2C65 Phase 2 [13]
RGB-286638 DMEGOQP Haematological malignancy 2B33.Y Phase 1 [6]
AG-024322 DMY4WVK Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
PHA-793887 DM2Y4FG Solid tumour/cancer 2A00-2F9Z Phase 1 [14]
Oxazolyl methylthiothiazole derivative 1 DMZM6FW N. A. N. A. Patented [15]
PMID25991433-Compound-A1 DM89LF0 N. A. N. A. Patented [16]
KENPAULLONE DMAGVXW Discovery agent N.A. Patented [17]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Cyclin-dependent kinase 2 (CDK2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
R-roscovitine DMSH108 Non-small-cell lung cancer 2C25.Y Phase 2 [2]
Ro 31-7453 DM83QCL Solid tumour/cancer 2A00-2F9Z Phase 2 [12]
PHA848125 DMS2Q9G Thymic cancer 2C27 Phase 2 [18]
TG02 DMZFIGQ Anaplastic astrocytoma 2A00.0 Phase 1/2 [19]
NUV-422 DMQJQNT Malignant glioma 2A00.0 Phase 1/2 [20]
RGB-286638 DMEGOQP Haematological malignancy 2B33.Y Phase 1 [6]
FN-1501 DM7BMD6 Solid tumour/cancer 2A00-2F9Z Phase 1 [21]
AG-024322 DMY4WVK Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
PHA-793887 DM2Y4FG Solid tumour/cancer 2A00-2F9Z Phase 1 [14]
SNS-032 DMEITAS Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Retinoblastoma-associated protein (RB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Indomethacin DMSC4A7 Bursitis Approved [22]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [23]
Gefitinib DM15F0X Colon adenocarcinoma Approved [24]
Talazoparib DM1KS78 Breast cancer 2C60-2C65 Approved [25]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [26]
Trametinib DM2JGQ3 Melanoma 2C30 Approved [27]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [28]
Methotrexate DM2TEOL Anterior urethra cancer Approved [29]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [30]
Quercetin DM3NC4M Obesity 5B81 Approved [31]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Poly polymerase 1 (PARP1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [32]
Gefitinib DM15F0X Colon adenocarcinoma Approved [33]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [34]
Nitric Oxide DM1RBYG Hypertension BA00-BA04 Approved [35]
Citalopram DM2G9AE Acute coronary syndrome BA41 Approved [36]
Ciprofloxacin XR DM2NLS9 Acute gonococcal cervicitis Approved [37]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [36]
Colchicine DM2POTE Acute gout flare FA25.0 Approved [38]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [39]
Methotrexate DM2TEOL Anterior urethra cancer Approved [40]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Breast cancer type 1 susceptibility protein (BRCA1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [32]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [41]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [42]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [43]
Methotrexate DM2TEOL Anterior urethra cancer Approved [44]
Quercetin DM3NC4M Obesity 5B81 Approved [45]
Furazolidone DM3P6V7 Diarrhea ME05.1 Approved [46]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [47]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [48]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [49]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Breast cancer type 2 susceptibility protein (BRCA2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [50]
Quercetin DM3NC4M Obesity 5B81 Approved [45]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [48]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [51]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [52]
Testosterone DM7HUNW Hot flushes GA30 Approved [53]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [53]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [54]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [55]
Demecolcine DMCZQGK Solid tumour/cancer 2A00-2F9Z Approved [56]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By DNA repair protein RAD51 homolog 1 (RAD51)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [57]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [58]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [59]
Dactinomycin DM2YGNW Adult kidney Wilms tumor Approved [60]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [47]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [61]
Testosterone DM7HUNW Hot flushes GA30 Approved [53]
Quizartinib DM8Y4JS Acute myeloid leukaemia 2A60 Approved [62]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [53]
Leflunomide DMR8ONJ Arthritis FA20 Approved [63]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Fanconi anemia group D2 protein (FANCD2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [57]
Methotrexate DM2TEOL Anterior urethra cancer Approved [64]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [47]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [65]
Testosterone DM7HUNW Hot flushes GA30 Approved [53]
Acocantherin DM7JT24 Atrial fibrillation BC81.3 Approved [66]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [53]
Leflunomide DMR8ONJ Arthritis FA20 Approved [63]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [67]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [68]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cyclin-dependent kinase 12 (CDK12)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [69]
Methotrexate DM2TEOL Anterior urethra cancer Approved [70]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [67]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [55]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [71]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [72]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [73]
Carbamazepine DMZOLBI Epilepsy 8A60-8A68 Approved [74]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [75]
Urethane DM7NSI0 N. A. N. A. Phase 4 [76]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cyclin-dependent kinase 1 (CDK1) TTH6V3D CDK1_HUMAN Inhibitor [2]
Cyclin-dependent kinase 2 (CDK2) TT7HF4W CDK2_HUMAN Inhibitor [2]
Cyclin-dependent kinase 9 (CDK9) TT1LVF2 CDK9_HUMAN Inhibitor [2]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Breast cancer type 1 susceptibility protein (BRCA1) OT5BN6VH BRCA1_HUMAN Gene/Protein Processing [3]
Breast cancer type 2 susceptibility protein (BRCA2) OTF1XSV1 BRCA2_HUMAN Gene/Protein Processing [3]
Cyclin-dependent kinase 12 (CDK12) OTZUDGNU CDK12_HUMAN Gene/Protein Processing [3]
DNA repair protein RAD51 homolog 1 (RAD51) OTNVWGC1 RAD51_HUMAN Gene/Protein Processing [3]
Fanconi anemia group D2 protein (FANCD2) OTVEB5LF FACD2_HUMAN Gene/Protein Processing [3]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Protein Interaction/Cellular Processes [4]
Retinoblastoma-associated protein (RB1) OTQJUJMZ RB_HUMAN Post-Translational Modifications [4]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7379).
2 Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
3 CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer. Cell Rep. 2016 Nov 22;17(9):2367-2381. doi: 10.1016/j.celrep.2016.10.077.
4 Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol Cancer Ther. 2010 Aug;9(8):2344-53. doi: 10.1158/1535-7163.MCT-10-0324. Epub 2010 Jul 27.
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013 Dec;27(12):2366-75.
7 Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 7;113(19):4637-45.
8 Clinical pipeline report, company report or official report of BioTheryX.
9 Clinical pipeline report, company report or official report of Sumitomo Dainippon Pharma.
10 VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia. Leukemia. 2023 Feb;37(2):326-338.
11 ClinicalTrials.gov (NCT05560607) An Open-label, Non-randomized, Multiple-dose Study to Assess the Knockdown of Hepatic HSD17B13 mRNA Expression, Pharmacokinetics, Safety, and Tolerability Following Administration of AZD7503 in Participants With Non-alcoholic Fatty Liver Disease. U.S.National Institutes of Health.
12 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
13 P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models. Mol Cancer Ther. 2007 Mar;6(3):926-34.
14 A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected h... Cell Cycle. 2011 Mar 15;10(6):963-70.
15 Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
16 c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
17 Discovery of novel CDK1 inhibitors by combining pharmacophore modeling, QSAR analysis and in silico screening followed by in vitro bioassay. Eur J Med Chem. 2010 Sep;45(9):4316-30.
18 Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor. J Med Chem. 2009 Aug 27;52(16):5152-63.
19 Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor. Drug Metab Lett. 2012 Mar;6(1):33-42.
20 ClinicalTrials.gov (NCT04541225) Phase 1/2 Dose Escalation, Safety, Pharmacokinetics, and Efficacy Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors. U.S.National Institutes of Health.
21 Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia. J Med Chem. 2018 Feb 22;61(4):1499-1518.
22 Indomethacin inhibits cell growth of medullary thyroid carcinoma by reducing cell cycle progression into S phase. Exp Biol Med (Maywood). 2008 Nov;233(11):1433-40. doi: 10.3181/0804-RM-127. Epub 2008 Sep 12.
23 Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocr Relat Cancer. 2011 Apr 28;18(3):333-45. doi: 10.1530/ERC-10-0262. Print 2011 Jun.
24 Effects and mechanisms of betulinic acid on improving EGFR TKI-resistance of lung cancer cells. Environ Toxicol. 2018 Nov;33(11):1153-1159.
25 BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile. J Biochem Mol Toxicol. 2019 May;33(5):e22286. doi: 10.1002/jbt.22286. Epub 2019 Jan 23.
26 Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
27 Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin Cancer Res. 2012 Aug 15;18(16):4345-55. doi: 10.1158/1078-0432.CCR-11-3227. Epub 2012 Jun 25.
28 Sulindac induces specific degradation of the HPV oncoprotein E7 and causes growth arrest and apoptosis in cervical carcinoma cells. Cancer Lett. 2007 Jan 8;245(1-2):103-11. doi: 10.1016/j.canlet.2005.12.034. Epub 2006 Feb 20.
29 Melanoma coordinates general and cell-specific mechanisms to promote methotrexate resistance. Exp Cell Res. 2012 Jun 10;318(10):1146-59.
30 HMG-CoA reductase inhibitor simvastatin inhibits cell cycle progression at the G1/S checkpoint in immortalized lymphocytes from Alzheimer's disease patients independently of cholesterol-lowering effects. J Pharmacol Exp Ther. 2008 Jan;324(1):352-9. doi: 10.1124/jpet.107.128959. Epub 2007 Oct 10.
31 Inhibition of prostate cancer cell colony formation by the flavonoid quercetin correlates with modulation of specific regulatory genes. Clin Diagn Lab Immunol. 2004 Jan;11(1):63-9. doi: 10.1128/cdli.11.1.63-69.2004.
32 Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
33 Evidence of securin-mediated resistance to gefitinib-induced apoptosis in human cancer cells. Chem Biol Interact. 2013 Apr 25;203(2):412-22. doi: 10.1016/j.cbi.2013.03.011. Epub 2013 Mar 22.
34 Cigarette smoke and asbestos activate poly-ADP-ribose polymerase in alveolar epithelial cells. J Investig Med. 2001 Jan;49(1):68-76. doi: 10.2310/6650.2001.34092.
35 Apoptotic signaling pathways induced by nitric oxide in human lymphoblastoid cells expressing wild-type or mutant p53. Cancer Res. 2004 May 1;64(9):3022-9. doi: 10.1158/0008-5472.can-03-1880.
36 The antidepressants imipramine, clomipramine, and citalopram induce apoptosis in human acute myeloid leukemia HL-60 cells via caspase-3 activation. J Biochem Mol Toxicol. 1999;13(6):338-47. doi: 10.1002/(sici)1099-0461(1999)13:6<338::aid-jbt8>3.0.co;2-7.
37 Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res. 2000 Mar;6(3):891-900.
38 Investigation of molecular mechanisms underlying the antiproliferative effects of colchicine against PC3 prostate cancer cells. Toxicol In Vitro. 2021 Jun;73:105138. doi: 10.1016/j.tiv.2021.105138. Epub 2021 Mar 6.
39 Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer. Mol Cancer Ther. 2005 Feb;4(2):291-304.
40 Methotrexate induces poly(ADP-ribose) polymerase-dependent, caspase 3-independent apoptosis in subsets of proliferating CD4+ T cells. Clin Exp Immunol. 2007 May;148(2):288-95. doi: 10.1111/j.1365-2249.2007.03335.x. Epub 2007 Feb 7.
41 Cross-talk between non-genomic and genomic signalling pathways--distinct effect profiles of environmental estrogens. Toxicol Appl Pharmacol. 2010 Jun 1;245(2):160-70. doi: 10.1016/j.taap.2010.02.015. Epub 2010 Mar 4.
42 Pro-oxidant induced DNA damage in human lymphoblastoid cells: homeostatic mechanisms of genotoxic tolerance. Toxicol Sci. 2012 Aug;128(2):387-97. doi: 10.1093/toxsci/kfs152. Epub 2012 Apr 26.
43 Differential gene expression of sulindac-treated human breast epithelial cells. Int J Oncol. 2005 Dec;27(6):1727-36.
44 Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
45 Quercetin and Its Fermented Extract as a Potential Inhibitor of Bisphenol A-Exposed HT-29 Colon Cancer Cells' Viability. Int J Mol Sci. 2023 Mar 15;24(6):5604. doi: 10.3390/ijms24065604.
46 Involvement of the activation of Nrf2/HO-1, p38 MAPK signaling pathways and endoplasmic reticulum stress in furazolidone induced cytotoxicity and S phase arrest in human hepatocyte L02 cells: modulation of curcumin. Toxicol Mech Methods. 2017 Mar;27(3):165-172. doi: 10.1080/15376516.2016.1273424. Epub 2017 Jan 8.
47 Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
48 Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
49 Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
50 Cannabidiol and Oxygen-Ozone Combination Induce Cytotoxicity in Human Pancreatic Ductal Adenocarcinoma Cell Lines. Cancers (Basel). 2020 Sep 27;12(10):2774. doi: 10.3390/cancers12102774.
51 Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders. Cancer Genet Cytogenet. 2010 Jun;199(2):110-20. doi: 10.1016/j.cancergencyto.2010.02.010.
52 THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
53 Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
54 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
55 Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
56 Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
57 Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells. Toxicol Sci. 2023 Feb 17;191(2):227-238. doi: 10.1093/toxsci/kfac131.
58 mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels. Cancer Sci. 2008 Oct;99(10):1992-2003. doi: 10.1111/j.1349-7006.2008.00955.x.
59 Propolis alleviates 4-aminobiphenyl-induced oxidative DNA damage by inhibition of CYP2E1 expression in human liver cells. Environ Toxicol. 2021 Aug;36(8):1504-1513. doi: 10.1002/tox.23147. Epub 2021 Apr 13.
60 Unpredicted Downregulation of RAD51 Suggests Genome Instability Induced by Tetrachlorobenzoquinone. Chem Res Toxicol. 2016 Dec 19;29(12):2184-2193. doi: 10.1021/acs.chemrestox.6b00369. Epub 2016 Nov 21.
61 Molecular characterization of a toxicological tipping point during human stem cell differentiation. Reprod Toxicol. 2020 Jan;91:1-13. doi: 10.1016/j.reprotox.2019.10.001. Epub 2019 Oct 7.
62 Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3. Arch Toxicol. 2022 Jan;96(1):177-193. doi: 10.1007/s00204-021-03174-1. Epub 2021 Oct 19.
63 Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
64 Methotrexate modulates folate phenotype and inflammatory profile in EA.hy 926 cells. Eur J Pharmacol. 2014 Jun 5;732:60-7.
65 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
66 Ouabain, a cardiac glycoside, inhibits the Fanconi anemia/BRCA pathway activated by DNA interstrand cross-linking agents. PLoS One. 2013 Oct 4;8(10):e75905. doi: 10.1371/journal.pone.0075905. eCollection 2013.
67 Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
68 Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
69 Oxidative stress modulates theophylline effects on steroid responsiveness. Biochem Biophys Res Commun. 2008 Dec 19;377(3):797-802.
70 Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
71 Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
72 Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
73 Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
74 Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
75 CRK7 modifies the MAPK pathway and influences the response to endocrine therapy. Carcinogenesis. 2009 Oct;30(10):1696-701. doi: 10.1093/carcin/bgp187. Epub 2009 Aug 3.
76 Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.